T cell gas, tumor brake
Three studies pump the therapeutic potential of PGC-1α
A trio of studies has converged on a common pathway, headed by the PPAR co-activator PGC-1α, to fight cancer and chronic infections by manipulating either T cell immunotherapies or the tumors themselves. While the findings reveal new biology underlying T cell exhaustion, they could also open the door to therapeutics against a hitherto under-exploited target.
PGC-1α is a transcriptional co-activator commonly referred to as the “master regulator of mitochondrial biogenesis.” Its overexpression has been shown to improve outcomes in preclinical models of a wide range of diseases, including atherosclerosis, acute kidney injury (AKI) and cancer, although some studies have shown the opposite - by demonstrating high PGC-1α activity helps tumor cells thrive...
BCIQ Company Profiles
BCIQ Target Profiles
AMP-activated protein kinase (AMPK)
Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1)
Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) (NRF2)
Peroxisome proliferation activated receptor (PPAR) alpha
Peroxisome proliferation activated receptor (PPAR) gamma
Peroxisome proliferation activated receptor (PPAR) gamma coactivator 1-alpha (PGC-1alpha) (PPARGC1A)